|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
TRANSPLANTATION
From the First Department of Pathology; and Department
of Orthopedic Surgery, Transplantation Center, Kansai Medical
University, Moriguchi City, Osaka, Japan.
Intractable autoimmune diseases in chimeric resistant MRL/lpr mice
were treated by a new bone marrow transplantation (BMT) method
consisting of fractionated irradiation, 5.5 Gy × 2, followed by
intra-bone marrow (IBM) injection of whole bone marrow cells (BMCs)
from allogeneic normal C57BL/6 (B6) mice (5.5 Gy × 2 + IBM). In MRL/lpr mice treated with this method, the number of donor-derived cells in the bone marrow, spleen, and liver rapidly increased (almost 100% donor-derived cells by 14 days after the treatment), and the number of donor-derived hemopoietic progenitor cells concomitantly increased. Furthermore, donor-derived stromal cells
were clearly detected in the cultured bone pieces from MRL/lpr mice treated with 5.5 Gy × 2 + IBM. All the recipients thus
treated survived more than 1 year (> 60 weeks after birth) and
remained free from autoimmune diseases. Autoantibodies
decreased to almost normal levels, and abnormal T cells
(Thy1.2+/B220+/CD4 Using various autoimmune-prone mice, we have previously
shown that conventional allogeneic bone marrow transplantation (allo BMT) can be used to prevent and treat a range of autoimmune
diseases.1-6 These findings have recently been confirmed
even in humans.7-15 However, in humans, the success rate
of BMT across major histocompatibility complex (MHC) barriers is
lowered by graft-versus-host disease (GVHD), graft rejection, and
incomplete T-cell recovery. Therefore, autologous BMT (auto BMT) or
peripheral blood stem cell transplantation (auto PBSCT) is the
preferred treatment for autoimmune diseases.16-18 There
have, however, been reports on the rapid recurrence or persistence of
autoimmune diseases after auto BMT or auto PBSCT.19
Therefore, it is important to establish a safe new method for
allo BMT.
We have recently found that the MRL/lpr mouse is a suitable model for
establishing a safe new strategy for allo BMT because the MRL/lpr mouse
itself is radiosensitive (< 8.5 Gy), whereas the abnormal hemopoietic
stem cells (HSCs) of the MRL/lpr mouse are radioresistant (> 8.5 Gy);
conventional BMT (8.5 Gy irradiation plus allo BMT) has a transient
effect on autoimmune diseases, which recur 3 months after the
BMT.20 However, we have found that BMT plus bone grafts
(to recruit donor stromal cells) completely prevents the recurrence of
autoimmune diseases in MRL/lpr mice21; donor-derived
stromal cells seem to play a crucial role in successful allo
BMT,21,22 because there is an MHC restriction between HSCs
and stromal cells.23 We have, however, found that the
combination of BMT plus bone grafts has no effect on the treatment of
autoimmune diseases in MRL/lpr mice,24 because MRL/lpr
mice become more radiosensitive after the onset of lupus nephritis due
to uremic enterocolitis. To reduce the cytotoxic effect of radiation on the intestine, we carried out fractionated irradiation and attempted to
devise a new strategy.
Recently, we have found that most donor HSCs are trapped and retained
in the liver when they are injected either via the portal vein (PV) or
intravenously (IV),25 and that the HSCs induce anergy to
host CD8+ T cells.26 In addition, we have
found a strategy (the PV plus the supplemental IV injections of donor
whole bone marrow cells [BMCs]) that induces persistent tolerance in
the skin allograft system.27 On the basis of these
findings, we have very recently established a new strategy for allo
BMT: fractionated irradiation (5.5 Gy × 2) and the PV plus IV
injections of whole BMCs.28 However, this method has 2 drawbacks for patients: laparoscope-guided injection of BMCs via the PV
is necessary, and an additional IV injection is essential for obtaining
a 100% success rate.28 We have analyzed the mechanism
underlying the tolerance induced by the PV injection of BMCs and noted
the importance of donor-derived stromal cells trapped in the liver,
which facilitate the proliferation and differentiation of donor HSCs.
Based on these findings, we attempted to inject whole BMCs (including
stromal cells) directly into the bone marrow (intra-bone marrow
[IBM] injection). In the present study, we show that IBM-BMT is a
powerful strategy for the treatment of intractable autoimmune diseases
in chimeric resistant MRL/lpr mice; IBM-BMT reduces the radiation dose
from 5.5 Gy × 2 to 5 Gy × 2, and obviates the need for the
supplemental IV injection of BMCs.
Mice
Preparation of donor BMCs and IBM injection of BMCs
PV injection of BMCs The BMCs were injected via the PV, as described previously.25 In brief, a midline incision was made on the abdomen to expose the viscera. The donor BMCs (3 × 107/300 µL) were injected via the superior mesenteric vein using a 27-gauge needle.Experimental protocols The onset of autoimmune diseases in MRL/lpr mice was monitored by proteinuria (> 2.5+) and lymphadenopathy. The mice (4-5 months of age) with autoimmune diseases were irradiated in fractionated doses (5.5 Gy × 2 = 11 Gy; 4-hour interval). One day after the irradiation, the mice were transplanted with the whole BMCs (3 × 107) by IBM injections (abbreviated as 5.5 Gy × 2 + IBM). Two groups were prepared as controls. The first group consisted of mice that were irradiated (5.5 Gy × 2) and transplanted with the whole BMCs (3 × 107) via the PV (abbreviated as 5.5 Gy × 2 + PV). The second group of mice was irradiated (5.5 Gy × 2) and transplanted with the whole BMCs (3 × 107) via the tail vein (abbreviated as 5.5 Gy × 2 + IV). Furthermore, recipients that had received reduced irradiation doses (5 Gy × 2, or 4.5 Gy × 2) plus IBM-BMT, PV-BMT, and IV-BMT were also prepared.Preparation of hepatic mononuclear cells (HMNCs) The HMNCs were prepared as described previously.28 In brief, the liver was perfused with collagenase (Type IV, 400 U/mL; Sigma Chemical, St Louis, MO) via the PV, and then incubated at 37°C for 40 minutes. A single-cell suspension was placed on Lympholyte-Mammal density solution (1.0860 g/mL; Cedarlane Laboratories, Hornby, ONT, Canada), and centrifuged for 30 minutes at 2800 rpm. The HMNCs were collected from the defined layer at the interface.Analyses for surface marker antigens The spleen cells, HMNCs, and BMCs were prepared from the recipient mice, and the cells were then stained with fluorescein isothiocyanate (FITC)-conjugated anti-H-2Db and phycoerythrin (PE)-conjugated anti-H-2Kk mAbs (Pharmingen, San Diego, CA) to identify the donor-derived cells. The cell surface phenotypes were also analyzed by FITC- or PE-conjugated mAbs against Thy1.2, B220, CD4, CD8, CD11b, and Gr-1 (Pharmingen). Furthermore, the cells were stained with biotinylated mAbs against lineage (Lin) markers (anti-CD4, anti-CD8 [Caltag, Burlingame, CA], anti-B220, anti-Gr-1, and anti-CD11b mAbs [Pharmingen]), followed by streptavidin-RED670 (Gibco BRL, Rockville, MD), then further stained with PE-anti-c-kit mAb and FITC-anti-H-2Db or anti-H-2Kk (Pharmingen). The cells with the immunophenotype of Lin /c-kit+/H-2b+ were categorized
as donor-derived hemopoietic progenitors. The stained cells were
analyzed by a FACScan (Becton Dickinson, Mountain View, CA).
Analyses for donor-derived stromal cells To prepare the bone marrow-derived stromal cells, the humeri from which the BMCs had been extensively washed out were cut into pieces, and the bone pieces were then cultured in a flask containing RPMI with 10% fetal bovine serum (FBS) at 37°C in 5% CO2 in air. The medium in the culture flask was replaced with the same volume of fresh medium weekly. Three weeks later, nonadherent cells, if any, were extensively removed, and the adherent cells were then collected from the surface of the flask using Cell Dissociation Solution (Sigma). To detect donor-derived stromal cells, the cultured cells were stained with anti-PA6 mAbs, which were reactive to the stromal cells,29 followed by PE-anti-rat IgM (Pharmingen). After blocking with normal rat IgM (Pharmingen), the cells were further stained with FITC-anti-H-2Db or anti-H-2Kk mAb, and analyzed by a FACScan. The cultured cells stained with the isotype-matched immunoglobulins served as a negative control.Measurement of autoantibodies Rheumatoid factors (RFs; IgG and IgM) and antisingle-stranded DNA (ssDNA) Abs (IgG and IgM) in the sera of the recipient mice were determined by a standard enzyme-linked immunosorbent assay (ELISA) as described previously.28 Autoantibodies were measured by absorbance at OD 405 nm, which is the maximum absorbance using the phosphatase substrate tablet (Sigma 104; Sigma).Analyses for immunologic functions Antibody production against sheep red blood cells (SRBCs) and mixed leukocyte reaction (MLR) were performed as immunologic functions of the treated mice. Anti-SRBC antibody response was evaluated, as described previously.28 In brief, the spleen cells (4 × 106) were cultured with the same number of SRBCs for 5 days, and anti-SRBC antibody production was measured by the modified Jerne plaque-forming cell (PFC) assay. MLR was performed as follows. The splenic T cells (2 × 105) were cultured with 2 × 105 responder T cells and 2 × 105 irradiated (12 Gy) stimulator spleen cells for 72 hours and pulsed with 0.5 µCi of [3H]-thymidine for the last 16 hours of the culturing period.Pathologic findings The kidneys of the recipient mice were removed and fixed in 10% formalin, and the sections were stained with hematoxylin and eosin (H-E). For the immunofluorescence study, the specimens were frozen in dry ice/acetone, as previously described.6 Briefly, 3-µm sections were stained with FITC-conjugated rabbit antimouse IgG or FITC-conjugated antimouse C3 (Medical and Biological Laboratories, Nagoya, Japan).At 14 days after the treatment with 5.5 Gy × 2 + IBM, the tibia (directly injected with the BMCs) and the femur (not injected with BMCs) were removed and fixed in 10% formalin, and the sections were then stained with H-E. As control groups, the tibias and femurs of the mice treated with 5.5 Gy × 2 + IV were stained with H-E. For the immunofluorescence study, the bone marrow specimens were frozen, and sectioned samples were stained with anti-PA6 mAb followed by PE-antirat IgM, then blocked by normal rat IgM. These sections were further stained with FITC-anti-H-2Db or anti-H-2Kk mAbs. The stained samples were examined on a confocal laser scanning microscope (LSM-GB200, Olympus, Tokyo, Japan) equipped with a × 20 objective lens. Statistical analyses Statistical analyses of the survival rate of the recipient mice were performed using a log-rank test.Proteinuria Proteinuria was measured using testing papers (Albustix, Miles-Sankyo, Tokyo, Japan).
Survival rates after BMT The MRL/lpr mice with lymphadenopathy and a high level of proteinuria (after the onset of autoimmune diseases) were treated with BMT via the IBM, PV, or IV. As shown in Figure 1A, all the mice treated with 8.5 Gy + IV died within 4 weeks due to the side effects of radiation, as we previously reported.24 The ineffectiveness of BMT via the IV was again observed when the recipients received fractionated irradiation to reduce the side effects of radiation (5.5 Gy × 2 + IV): all the mice died within 30 weeks (Figure 1A). In contrast, more than 70% of MRL/lpr mice treated with fractionated irradiation and BMT via the PV (5.5 Gy × 2 + PV) survived more than 1 year after the treatment. These findings suggest that the PV injection of BMCs is more effective in prolonging survival than the IV injection. The supplemental injection via the IV (5.5 Gy × 2 + PV + IV) completely cured the autoimmune diseases in the MRL/lpr mice; 100% of the mice survived 1 year after the treatment, indicating that the supplemental IV injection is helpful for successful engraftment, as we previously reported.28
We next examined whether the radiation dose could be reduced. MRL/lpr mice treated with either 5 Gy × 2 + PV or 5 Gy × 2 + PV + IV showed survival rates of 30% and 50%, respectively (Figure 1B). These findings indicate that the 5 Gy × 2 irradiation alone (without using cyclophosphamide) is insufficient to prevent graft rejection.24 Therefore, we attempted to establish a new method for BMT that prevents the graft rejection even under the reduced radiation dose. BMCs were injected directly into the bone marrow (IBM). Surprisingly, all the recipients that received IBM-BMT survived 48 weeks after the treatment without showing any signs of graft rejection or recurrence of autoimmune diseases when treated with 5 Gy × 2 + IBM (Figure 1B) as well as 5.5 Gy × 2 + IBM (Figure 1A). Furthermore, more than 85% of the MRL/lpr mice survived 30 weeks after the treatment even when treated with 4.5 Gy × 2 + IBM (Figure 1B). When 5 × 106 cells were injected directly into the femur cavity, the same result was obtained as when 3 × 107 cells were injected (data not shown); the data shown here are for 3 × 107 BMCs, because we wanted to compare the effectiveness of IBM-BMT with previous data on PV-BMT and IV-BMT.24,28 Analyses of donor-derived hemopoietic cells The percentages of the donor-derived hemopoietic cells in the bone marrow, spleen, and liver were kinetically examined on days 3, 7, 10, and 14 after the treatment with 5.5 Gy × 2 + IBM, and compared with those from the recipients that received 5.5 Gy × 2 + IV or 5.5 Gy × 2 + PV. As shown in Figure 2B, when treated with 5.5 Gy × 2 + IV, the percentages of donor-derived cells in the hemopoietic organs had increased by 10 days after the treatment, but then gradually decreased. When treated with 5.5 Gy × 2 + PV, the percentages of donor-derived cells had rapidly increased by 10 days and reached almost 100% on day 14. When treated with 5.5 Gy × 2 + IBM, the percentages of donor-derived cells remarkably increased to approximately 60% both in the bone marrow from the tibia (directly injected with BMCs) and the femur (not injected with BMCs) and to approximately 40% in the spleen on day 3 after the treatment, reaching almost 100% in both the bone marrow (the tibia and femur) and spleen on day 10 (Figure 2B). The representative FACS profiles (on days 3 and 10) confirming the kinetic data are shown in Figure 2A.
These findings were confirmed histologically; both the tibia (Figure
3A; directly injected with the BMCs) and
the femur (Figure 3B; not injected with BMCs) showed a remarkable
proliferation of hemopoietic cells in comparison with the tibia (Figure
3C) and femur (Figure 3D) of the mice treated with 5.5 Gy × 2 + IV when examined 14 days after the treatment. The tibia and
femur of the mice treated with 5.5 Gy × 2 + IV showed
hypoplastic bone marrow. Furthermore, the tibia from the recipients
that had been treated with 5.5 Gy × 2 + IV and injected with
30 µL medium alone (instead of BMCs), also showed hypoplastic bone
marrow, and the most mice died within 2 months (data not shown). This
indicates that the IBM injection actually facilitates the donor cell
engraftment and does not merely modulate the homing pattern of
BMCs.
Donor-derived cells with mature lineage markers (B220+,
CD4+, CD8+, CD11b+, and
Gr-1+) had also been generated in the bone marrow, spleen,
and liver by 14 days after the treatment with 5.5 Gy × 2 + IBM (Table 1), and remained at normal
levels 1 year after the treatment (data not shown). In contrast, 14 days after the treatment with 5.5 Gy × 2 + IV, hardly any
donor-derived cells bearing lineage markers could be detected in the
hemopoietic organs. These findings indicate that IBM-BMT significantly
facilitates the early engraftment and continuous proliferation and
differentiation of donor cells.
Analyses of donor-derived progenitor cells The engraftments of hemopoietic stem cells and progenitor cells are crucially important to maintain hemopoiesis. Because many mice (> 10 mice in each group) are necessary to analyze the pluripotent hemopoietic stem cells (P-HSCs) (c-kit <low/Lin),30 we examined the
frequency of donor-derived progenitor cells (c-kit+/Lin cells) in the hemopoietic organs.
As shown in Figure 4B, the percentages of
donor-derived progenitor cells
(H-2b+/c-kit+/Lin cells) in the
bone marrow (either in the tibia or femur where the BMCs were directly
injected or not injected, respectively) significantly increased when
treated with 5.5 Gy × 2 + IBM in comparison with 5.5 Gy × 2 + PV or 5.5 Gy × 2 + IV 14 days after the
treatment, and almost no progenitor cells of host origin
(H-2k+/c-kit+/Lin cells) could be
detected (Figure 4B, dashed line; it should be noted that the residual
host cells gradually decreased to 0% when treated with 5.5 Gy × 2 + IBM, as shown in Figure 2B). As shown in Figure 4A, 14 days
after the treatment with 5.5 Gy × 2 + IBM, almost all the
progenitor cells were of donor origin. It should be noted that
the percentages of donor-derived progenitor cells had increased even in
the spleen of recipients treated with 5.5 Gy × 2 + IBM,
although the percentages in the spleens in the other groups had
decreased. The percentages of donor-derived progenitor cells in the
bone marrow remained more than 3% up to 1 year after the treatment
(data not shown). These findings indicate that IBM-BMT accelerates and
maintains the proliferation of donor-derived progenitor cells,
possibly P-HSCs.
Analyses of donor-derived stromal cells We have recently found that donor-derived stromal cells are necessary for successful allogeneic BMT, because there is an MHC restriction between P-HSCs and stromal cells.23 To examine whether donor-derived stromal cells are actually present in the recipient bone marrow after the treatment, bone pieces without BMCs from the treated MRL/lpr mice were cultured for 3 weeks, and the cultured stromal cells were then collected. The number of adherent cells from the recipient bone treated with 5.5 Gy × 2 + IV was 1.5 ± 1.5 × 104/culture (humerus), and that of 5.5 Gy × 2 + PV was 4.2 ± 1.2 × 105, whereas that of 5.5 Gy × 2 + IBM was 5.9 ± 0.7 × 105 (the mean ± SD of 5 mice). Furthermore, as shown in Figure 5, these cultured stromal cells from the recipients treated with 5.5 Gy × 2 + IBM were positive for H-2Db and stained by stromal cell-specific anti-PA6 mAb,29 indicating the replacement of stromal cells by donor-derived stromal cells. This was also confirmed by the immunohistochemical analyses where the stromal cells that were stained by anti-PA6 mAb were also detected by anti-H-2Db mAb (Figure 3E, cells colored yellow), but not by anti-H-2Kk mAb (data not shown), again indicating that the stromal cells were of donor origin. These findings indicate that the donor-derived stromal cells can efficiently proliferate in the recipient bone marrow when IBM-BMT is carried out. In addition, abnormal T cells (Thy1.2+/B220+) of MRL/lpr mice disappeared, and all the cells in the spleen and lymph nodes had been replaced by donor-derived cells by 40 weeks after the treatment of 5.5 Gy × 2 + IBM (at the age of 60 weeks), indicating that the hematolymphoid cells are completely reconstituted with donor-derived cells (data not shown).
Immunologic and immunopathologic findings in MRL/lpr mice treated with 5.5 Gy × 2 + IBM Nontreated MRL/lpr mice at the age of 20 weeks showed increased anti-ssDNA Abs (IgG and IgM) and RFs (IgG and IgM), whereas MRL/lpr mice treated with 5.5 Gy × 2 + IBM showed almost normal values in all these parameters 40 weeks after the treatment (Figure 6). In addition, the immunologic functions were completely restored after the treatment (40 weeks) when assessed by in vitro anti-SRBC antibody response (number of PFC/culture: 198.3 ± 16.1 in the recipients treated with 5.5 Gy × 2 + IBM and 257.7 ± 13.2 in normal B6 mice). Furthermore, newly developed T cells showed tolerance to both host (MRL/lpr)-type and donor (B6)-type MHC determinants, whereas they showed normal responsiveness to third party (BALB/c) cells when examined in MLR (data not shown). These findings indicate that successful cooperation can be achieved among newly developed T cells, B cells, and antigen-presenting cells in MRL/lpr mice treated with 5.5 Gy × 2 + IBM.
The glomeruli in the nontreated MRL/lpr mice showed the proliferation
of mesangial cells and marked IgG deposits (Figure
7A,B), whereas the glomeruli in the
MRL/lpr mice treated with 5.5 Gy × 2 + IBM showed normal
appearance without IgG deposits (Figure 7C,D).
Allogeneic BMT has become an established technique and is generally performed as the treatment of preference for leukemia and aplastic anemia. However, problems such as graft failure and graft-versus-host reaction have been reported; only 60% of patients with leukemia or 55% of patients with aplastic anemia survive disease free.31-33 We have previously found that allo BMT via the IV or the PV with or without bone grafts (to recruit donor stromal cells) has curative effects on autoimmune diseases in various autoimmune-prone mice except MRL/lpr mice.34,35 In humans, allo BMT has been performed on patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, and Crohn disease, and has been reported to be effective in treating these autoimmune diseases.7-13 Moreover, these diseases do not recur after allo BMT during long-term observation (range 7-20 years).14,15 In general, patients with autoimmune diseases will have undergone long-term administration of anti-inflammatory drugs, immunosuppresants, and cytotoxic reagents, all of which produce various side effects. Therefore, a safe new strategy for allo BMT has been long awaited. We have previously found that MHC-matched stromal cells are required for the proliferation and differentiation of P-HSCs, and that the donor-derived stromal cells play a crucial role in successful allo BMT.21-27 In addition, we have recently found that allo BMT via the PV plus supplemental IV injections completely cures autoimmune diseases in chimeric-resistant MRL/lpr mice even after the onset of autoimmune diseases, and that all the recipients thus treated survived more than 1 year without any recurrence of the diseases.28 These findings suggest that the PV injection of donor whole BMCs (including donor stromal cells) creates a suitable microenvironment in the liver, and that this facilitates the proliferation of donor HSCs in collaboration with MHC-matched donor stromal cells. Indeed, we have very recently found that donor-derived cells trapped in the liver play a crucial role in the success of BMT36; when adherent cell-depleted BMCs were injected, 75% of recipients died within 90 days, whereas all the recipients injected with adherent cell-depleted BMCs with cultured stromal cells survived more than 80 days.37 Although this method is effective, there are risks associated with the abdominal section, and supplemental IV injection is required. In addition, the radiation dose could not be reduced to 5 Gy × 2. It has been reported that the transplantation of a large number of HSCs overcomes MHC barriers.38,39 We have very recently found that a large number of HSCs can proliferate in collaboration with MHC-mismatched stromal cells,40 although there is an MHC restriction between HSCs and stromal cells.23 However, in humans, this strategy suffers from the difficulty of obtaining a large number of HSCs from one donor. In the present study, we attempted to inject the allogeneic whole BMCs (including a small number [< 3%] of T cells, HSCs, and stromal cells) directly into the recipient bone marrow cavity (IBM-BMT) so that donor-derived hemopoietic cells including stromal cells can effectively accumulate in the bone marrow. To our knowledge, this is the first report on the effect of IBM-BMT on autoimmune diseases in MRL/lpr mice, although there are a few reports in which bone marrow cells aspirated from the bone marrow cavity were used for serial BMT41 and gene therapy.42 All the MRL/lpr mice survived more than 1 year (> 60 weeks after birth) without the recurrence of autoimmune diseases, and immunologic functions were completely restored even when the radiation dose was reduced to 5 Gy × 2 (5 Gy × 2 + IBM). It should be noted that more than 85% of MRL/lpr mice treated only with 4.5 Gy × 2 + IBM also survived more than 30 weeks after the treatment. These findings suggest that IBM-BMT can be used to treat intractable autoimmune diseases under reduced radiation doses without using any immunosuppressants. This seems to be attributable to the enhanced engraftment of donor-derived cells in the early stage after this treatment; the percentage of donor-derived cells reached almost 100%, and donor-derived cells bearing mature lineage markers were generated in the bone marrow, spleen, and liver by 14 days after the treatment with IBM-BMT (Figure 2 and Table 1). Furthermore, the percentages of donor-derived progenitor cells in the bone marrow of both the tibia (BMCs were directly injected) and the femur (BMCs were not injected) significantly increased by 14 days after the treatment (Figure 4). Therefore, the IBM injection rapidly accelerates the proliferation of donor-derived progenitor cells and simultaneously maintains hemopoietic progenitor cells, resulting in the recovery of hemopoiesis. In the present study, we have shown that IBM-BMT is, so far, the best strategy for allo BMT: (1) no GVHD develops even if T cells are not depleted from the bone marrow; (2) no graft failure occurs even if the dose of radiation as the conditioning for BMT is reduced to 5 Gy × 2; (3) hemopoietic recovery is rapid; and (4) the restoration of T-cell functions is complete even in donor-recipient combinations across the MHC barriers. We believe that this IBM-BMT is applicable to humans, because intraosseous (IO) infusion (IBM injection) is now an established method for administering fluids, drugs, and blood to critically ill patients, particularly infants.43-46 Indeed, Hagglund and coworkers have recently compared the effectiveness of IO infusion with that of IV infusion in human allo BMT47; they have concluded that allo BMT can be safely performed by IO infusion, but the incidences of acute and chronic GVHD, transplantation-related mortality, and survival rates are similar. However, they aspirated the donor BMCs from the iliac bones and infused these BMCs into the iliac bones of the recipients. Using cynomolgus monkeys, we have just established a new method (perfusion method) for collecting BMCs from the long bones (femur, humerus, and so on) without peripheral blood contamination.48 This method has various merits: (1) no GVHD develops even in cynomolgus monkeys, because the percentage of T cells in the BMCs thus collected is less than 3%, and (2) a large number of BMCs can be collected quickly and safely. We therefore believe that this method (IBM-BMT) will become a powerful new strategy for not only allo BMT but also organ transplantation in conjunction with BMT.
The authors thank Ms Y. Tokuyama, Ms M. Shinkawa, Ms S. Miura (First Department of Pathology) and Mr K. Kobayashi (Central Research Center) for their expert technical assistance, and Mr Hilary Eastwick-Field and Ms K. Ando for their help in the preparation of the manuscript.
Submitted August 7, 2000; accepted January 17, 2001.
Supported by a grant from Haiteku Research Center of the Ministry of Education, a grant-in-aid for scientific research (B) 11470062, grants-in-aid for scientific research on priority areas (A)10181225 and (A)11162221, a grant from Millennium of Science and Technology Agency, and also a grant from Japan Immunoresearch Laboratories Co, Ltd (JIMRO).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Susumu Ikehara, First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan; e-mail: ikehara{at}takii.kmu.ac.jp.
1.
Ikehara S, Good RA, Nakamura T, et al.
Rationale for bone marrow transplantation in the treatment of autoimmune disease.
Proc Natl Acad Sci U S A.
1985;82:2483-2487
2.
Ikehara S, Ohtsuki H, Good RA, et al.
Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation.
Proc Natl Acad Sci U S A.
1985;82:7743-7747
3.
Oyaizu N, Yasumizu R, Inaba-Miyama M, et al.
(NZW x BXSB)F1 mouse, a new model of idiopathic thrombocytopenic purpura.
J Exp Med.
1988;167:2017-2022 4. Nakagawa T, Nagata N, Hosaka H, Ogawa R, Nakamura K, Ikehara S. Prevention of autoimmune inflammatory polyarthritis in male New Zealand black/KN mice by transplantation of bone marrow cells plus bone (stromal cells). Arthritis Rheum. 1993;36:263-268[Medline] [Order article via Infotrieve].
5.
Nishimura M, Toki J, Sugiura K, et al.
Focal segmental glomerular sclerosis, a type of intractable chronic glomerulonephritis, is a stem cell disorders.
J Exp Med.
1994;179:1053-1058
6.
Soe T, Ishida H, Inaba M, et al.
Bone marrow transplantation as a strategy for treatment of non-insulin-dependent diabetes mellitus in KK-Ay mice.
J Exp Med.
1992;176:1233-1238 7. Baldwin JL, Strob R, Thomas ED, Mannik M. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum. 1977;20:1043-1048[Medline] [Order article via Infotrieve]. 8. Jacobs P, Vincent MD, Martell RW. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anemia. Bone Marrow Transplant. 1986;1:237-239[Medline] [Order article via Infotrieve]. 9. Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol. 1993;20:137-140[Medline] [Order article via Infotrieve]. 10. Eedy DJ, Burrows D, Bridges JM, Jones FF. Clearance of severe psoriasis after allogeneic bone marrow transplantation. Br Med J. 1990;300:908. 11. Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1992;9:31-33[Medline] [Order article via Infotrieve]. 12. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation. A new treatment for severe autoimmune diseases? Stem Cells. 1994;12:125-135[Medline] [Order article via Infotrieve]. 13. Sullivan KM,Furst DE, eds. Role of Hematopoietic Stem Cell Transplantation for Autoimmune Diseases. Vol 24. Seattle, WA: Fred Hutchinson Cancer Research Center. J Rheumatol.; 1997:1-102. 14. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune diseases in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;24:23-29. 15. Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum. 1998;41:453-459[CrossRef][Medline] [Order article via Infotrieve].
16.
Marrmont AM.
Stem cell transplantation for severe autoimmune diseases: progress and problems.
Haematologica.
1998;83:733-743 17. Burt RK. BMT for severe autoimmune diseases: an idea whose time has come. Oncology. 1997;11:1001-1024[Medline] [Order article via Infotrieve]. 18. Tyndall A, Black C, Finke J, et al. Treatment of systemic sclerosis with autologous haematopoietic stem cell transplantation. Lancet. 1997;349:254[Medline] [Order article via Infotrieve].
19.
Euler HH, Marmont AM, Bacigalupo A, et al.
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation.
Blood.
1996;88:3621-3625
20.
Ikehara S, Yasumizu R, Inaba M, et al.
Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation.
Proc Natl Acad Sci U S A.
1989;86:3306-3310 21. Ishida T, Inaba M, Hisha H, et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. J Immunol. 1994;152:3119-3127[Abstract]. 22. Hisha H, Nishino T, Kawamura M, Adachi S, Ikehara S. Successful bone marrow transplantation by bone grafts in chimeric-resistant combination. Exp Hematol. 1994;23:347-352.
23.
Hashimoto F, Sugiura K, Inoue K, Ikehara S.
Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo.
Blood.
1997;89:49-54
24.
Takeuchi K, Inaba M, Miyashima S, Ogawa R, Ikehara S.
A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice.
Blood.
1998;91:4616-4623 25. Zhang Y, Yasumizu R, Sugiura K, et al. Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection. Eur J Immunol. 1994;24:1558-1565[Medline] [Order article via Infotrieve]. 26. Sugiura K, Kato K, Hashimoto F, et al. Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells. Immunobiology 1997;197:460-477[Medline] [Order article via Infotrieve].
27.
Morita H, Sugiura K, Inaba M, et al.
A strategy for organ allografts without using immunosuppressants or irradiation.
Proc Natl Acad Sci U S A.
1998;95:6947-6952
28.
Kushida T, Inaba M, Takeuchi K, Sugiura K, Ogawa R, Ikehara S.
Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marow transplantation.
Blood.
2000;95:1862-1868 29. Izumi-Hisha H, Soe T, Ogata H, Inaba M, Ikehara S, Kawai M. Monoclonal antibodies against a preadipose cell line (MC3T3-G2/PA6) which can support hemopoiesis. Hybridoma. 1991;10:103-112[Medline] [Order article via Infotrieve].
30.
Doi H, Inaba M, Yamamoto Y, et al.
Pluripotent hemopoietic stem cells are c-kit<low.
Proc Natl Acad Sci U S A.
1997;94:2513-2517 31. Storb R. Bone marrow transplantation for aplastic anemia. In: Forman SJ,Blume KG,Thomas DE, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific; 1994:584-594.
32.
Sasazuki T, Juji T, Morishima Y, et al.
Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor.
N Engl J Med.
1999;339:1177-1185 33. Hernandez-Boluda JC, Marin P, Carreras E, et al. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. Hematologica. 1999;84:26-31[Medline] [Order article via Infotrieve]. 34. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol. 1998;99:116-132[CrossRef][Medline] [Order article via Infotrieve]. 35. Ikehara S. Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment [review]. Int J Mol Med. 1998;1:5-16[Medline] [Order article via Infotrieve]. 36. Fan T, Hisha H, Jin T, et al. Successful allogeneic bone marrow transplantation (BMT) by injection of bone marrow cells via portal vein: stromal cells as BMT-facilitating cells. Stem Cells. 2001;19:144-150[CrossRef][Medline] [Order article via Infotrieve]. 37. Kushida T, Inaba M, Hisha H, et al. Crucial role of donor-derived stromal cells in successful treatment for intractable autoimmune diseases in MRL/lpr mice by BMT via portal vein. Stem Cells. In press. 38. Bachar-Lustig B, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1273[CrossRef][Medline] [Order article via Infotrieve]. 39. Reisner Y, Martelli MF. Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol. 2000;28:119-127[Medline] [Order article via Infotrieve]. 40. Sugiura K, Hisha H, Ishikawa J, et al. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vitro. Stem Cells. 2001;19:46-58[CrossRef][Medline] [Order article via Infotrieve]. 41. Verlinden SFF, van Es HHG, van Bekkum DW. Serial bone marrow sampling for long-term follow up of human hematopoiesis in NOD/SCID mice. Exp Hematol. 1998;26:627-639[Medline] [Order article via Infotrieve]. 42. Jin L, Zeng H, Chien S, et al. In vivo selection using a cell-growth switch. Nat Genet. 2000;26:64-66[CrossRef][Medline] [Order article via Infotrieve].
43.
Josefson A.
A new method of treatment 44. Tocantins LM, O'Neill JF. Infusion of blood and other fluids into the circulation via the bone marrow. Pro Soc Exp Biol Med. 1940;45:782-783[CrossRef]. 45. Spivey WH. Intraosseous infusions. J Pediatr. 1987;111:639-643[CrossRef][Medline] [Order article via Infotrieve].
46.
Morrison M, Samwick AA.
Intramedullary (sternal) transfusion of human bone marrow.
JAMA.
1940;115:1708-1711 47. Hagglund H, Ringden O, Agren B, et al. Intraossseous compared to intractable infusion of allogeneic bone marrow. Bone Marrow Transplant. 1998;21:331-335[CrossRef][Medline] [Order article via Infotrieve]. 48. Kuhsida T, Inaba M, Ikebukuro K, et al. A new method for bone marrow cell harvesting. Stem Cells 2000;18:453-456[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Mizokami, H. Hisha, S. Okazaki, T. Takaki, X.-L. Wang, C.-Y. Song, Q. Li, J. Kato, N. Hosaka, M. Inaba, et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells Haematologica, May 1, 2009; 94(5): 618 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Asada, T. Kushida, M. Umeda, K. Oe, H. Matsuya, T. Wada, K. Sasai, S. Ikehara, and H. Iida Prevention of corticosteroid-induced osteonecrosis in rabbits by intra-bone marrow injection of autologous bone marrow cells Rheumatology, May 1, 2008; 47(5): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shi, J. Li, L. Liao, B. Chen, B. Li, L. Chen, H. Jia, and R. C. Zhao Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice Haematologica, July 1, 2007; 92(7): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyata, G. Takemura, Y. Kawase, Y. Li, H. Okada, R. Maruyama, H. Ushikoshi, M. Esaki, H. Kanamori, L. Li, et al. Autophagic Cardiomyocyte Death in Cardiomyopathic Hamsters and Its Prevention by Granulocyte Colony-Stimulating Factor Am. J. Pathol., February 1, 2006; 168(2): 386 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Taichman Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche Blood, April 1, 2005; 105(7): 2631 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iwasaki, Y. Adachi, K. Minamino, Y. Suzuki, Y. Zhang, M. Okigaki, K. Nakano, Y. Koike, J. Wang, H. Mukaide, et al. Mobilization of Bone Marrow Cells by G-CSF Rescues Mice from Cisplatin-Induced Renal Failure, and M-CSF Enhances the Effects of G-CSF J. Am. Soc. Nephrol., March 1, 2005; 16(3): 658 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wysoczynski, R. Reca, J. Ratajczak, M. Kucia, N. Shirvaikar, M. Honczarenko, M. Mills, J. Wanzeck, A. Janowska-Wieczorek, and M. Z. Ratajczak Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient Blood, January 1, 2005; 105(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Burt, L. Verda, D.-A. Kim, Y. Oyama, K. Luo, and C. Link Embryonic Stem Cells As an Alternate Marrow Donor Source: Engraftment without Graft-Versus-Host Disease J. Exp. Med., April 5, 2004; 199(7): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yahata, K. Ando, T. Sato, H. Miyatake, Y. Nakamura, Y. Muguruma, S. Kato, and T. Hotta A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow Blood, April 15, 2003; 101(8): 2905 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, T. Kimura, R. Asada, S. Harada, S. Yokota, Y. Kawamoto, Y. Fujimura, T. Tsuji, S. Ikehara, and Y. Sonoda SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection Blood, April 15, 2003; 101(8): 2924 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Marmont Lupus: tinkering with haematopoietic stem cells Lupus, November 1, 2001; 10(11): 769 - 774. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
represent donor-derived BMCs
collected from the tibia where the donor BMCs were directly injected,
and 
show donor-derived BMCs obtained from the femur where the donor
BMCs were not injected; 
indicates PV, and 
, IV.
, tibia; 
, femur), 5.5 Gy × 2 + PV (
), or 5.5 Gy × 2 + IV (
) are shown. The results are expressed as the mean ± SD of 6 mice. Symbols representing the sites of the injection of BMCs are shown
next to the right-hand figure. (
intraossal injections.
Acta Med Scand.
1934;81:550-564.